V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330009132 | 330005924 | 1.7 | 84.2 | Curative (C) | 2016-01-21 | 2016-07-28 | CISPLATIN + VINORELBINE | N | N | 330024671 | BORTEZOMIB |
| 330009133 | 330005925 | 1.85 | 72.2 | Curative (C) | 2015-03-16 | 2015-03-18 | Cyclophosphamide High Dose | 02 | N | 330024671 | HYDROXYCARBAMIDE |
| 330009134 | 330005926 | 1.82 | 35.9 | Palliative (P) | 2015-09-18 | 2015-09-18 | Cyclophosphamide High Dose | 2 | N | 330024676 | BEP |
| 330009135 | 330011015 | 1.82 | null | null | 2013-07-31 | 2013-08-01 | MELPHALAN | N | N | 330024703 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330009136 | 330011015 | 1.71 | 90.2 | Palliative (P) | 2014-06-03 | 2014-06-05 | STS Rhabdomyosarcoma RMS 2005 VA | N | Y | 330024703 | CAPECITABINE + CARBOPLATIN |
| 330009137 | 330005927 | null | 49.4 | Palliative (P) | 2018-05-19 | 2018-05-25 | AXITINIB | 02 | Y | 330024720 | CETUXIMAB + CISPLATIN + FU |
| 330009138 | 330005928 | 1.69 | 53 | Adjuvant (A) | 2016-11-06 | 2017-01-01 | LENALIDOMIDE | 01 | null | 330024726 | CETUXIMAB + CISPLATIN + FU |
| 330009139 | 330005929 | 1.71 | 21.6 | Palliative (P) | 2017-08-29 | 2017-08-29 | Alemtuzumab+Busulfan+CyclophosphMUD | 2 | N | 330024727 | ERLOTINIB |
| 330009140 | 330009231 | null | 66.9 | Palliative (P) | 2014-01-29 | 2014-02-11 | BOP | Y | N | 330024744 | VINCRISTINE |
| 330009141 | 330012890 | 1.79 | 67.4 | Disease modification (D) | 2017-01-21 | 2017-01-21 | CYTARABINE | 2 | N | 330024755 | CARBOPLATIN + VINORELBINE |
| 330009142 | 330012569 | 1.58 | 81.4 | Disease modification (D) | 2013-05-13 | 2013-05-14 | Clofarabine + Cytarabine | N | N | 330024769 | UKALL 2003 |
| 330009143 | 330005935 | 1.63 | 70.1 | Curative (C) | 2014-04-28 | 2014-05-02 | CHLORAMBUCIL + RITUXIMAB | 2 | N | 330024769 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330009144 | 330005937 | 1.7 | 74.5 | Curative (C) | null | 2015-09-04 | BEP 5 Day | null | null | 330024785 | CVD |
| 330009145 | 330005939 | null | 83 | null | 2015-11-08 | 2015-11-27 | Cladribine (subcut) 5 days | N | N | 330024813 | IFOSFAMIDE + PACLITAXEL |
| 330009146 | 330009236 | 1.53 | 38.3 | Adjuvant (A) | 2013-07-16 | 2013-07-29 | Doxorubicin + Olaratumab | 02 | N | 330024813 | DOXORUBICIN + HD MTX |
| 330009147 | 330005940 | 1.84 | 107 | Adjuvant (A) | 2015-09-30 | 2015-10-07 | AML16 Low Dose Cytarabine | N | N | 330024826 | IBRUTINIB |
| 330009148 | 330005941 | 1.66 | 59.4 | Palliative (P) | 2017-11-16 | 2017-11-19 | Capecitabine + Carboplatin + RT | 02 | N | 330024829 | CAPECITABINE + STREPTOZOCIN |
| 330009149 | 330005942 | 1.73 | 15.9 | Disease modification (D) | 2015-12-22 | 2015-12-23 | Bortezomib + CYCLOPHOSPHAMIDE | 02 | N | 330024832 | BEP |
| 330009150 | 330009238 | null | 69.6 | Curative (C) | 2013-03-19 | 2013-03-25 | CARBO + THIOTEPA + TOPOTECAN | N | null | 330024844 | TRIPLE INTRATHECAL |
| 330009151 | 330009238 | 1.73 | 60 | Palliative (P) | 2012-10-13 | 2013-12-15 | DE-ESCALATE TRIAL | N | N | 330024844 | BEP |
| 330009152 | 330005947 | null | 101 | Palliative (P) | 2014-12-10 | 2014-12-24 | MAP + MIFAMURTIDE | N | N | 330024857 | TRASTUZUMAB |
| 330009153 | 330005948 | 1.58 | 57 | Curative (C) | 2014-12-23 | 2014-12-30 | Cyclophosphamide+Fludara+TBI Allo | 01 | N | 330024868 | CARBOPLATIN + VINCRISTINE |
| 330009154 | 330005950 | null | 55 | Curative (C) | 2014-10-11 | 2014-10-21 | Cisplatin+Doxorubicin+Etoposide 28d | N | null | 330024868 | ICE |
| 330009155 | 330011024 | 1.76 | null | Curative (C) | 2015-03-20 | 2015-03-20 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | 02 | N | 330024869 | CISPLATIN + DOXORUBICIN + ETOPOSIDE |
| 330009157 | 330009243 | 0 | 78.8 | Palliative (P) | 2013-12-19 | 2013-12-21 | Sunitinib | N | null | 330024882 | CAPECITABINE |
| 330009158 | 330005955 | 1.87 | 74.6 | Not known (9) | null | 2015-11-27 | Clofarabine + Cytarabine | null | N | 330024888 | IPO |
| 330009159 | 330005958 | 1.84 | 91.6 | Palliative (P) | 2016-08-25 | 2016-08-25 | Topotecan (intravenous) | 02 | null | 330024888 | BEVACIZUMAB + IRINOTECAN |
| 330009160 | 330005959 | 1.71 | 18 | Palliative (P) | 2018-09-18 | 2019-01-07 | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 02 | N | 330024933 | CYTARABINE |
| 330009161 | 330011028 | 1.85 | 165 | Curative (C) | 2014-09-08 | 2014-09-15 | CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE + VINCRISTINE | N | N | 330024934 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330009162 | 330005960 | 1.8 | 104.9 | Palliative (P) | 2014-11-04 | 2014-11-06 | CARBOPLATIN + Cetuximab + FLUOROURACIL | N | N | 330024941 | CETUXIMAB + CISPLATIN + FU |
| 330009163 | 330005961 | 1.68 | null | Curative (C) | 2013-09-22 | 2013-09-22 | Cisplatin + Pemetrexed | N | N | 330024941 | CARBOPLATIN + DOCETAXEL |
| 330009164 | 330005962 | 0 | 47.8 | Palliative (P) | 2017-07-03 | 2017-08-05 | EP | N | N | 330024943 | OFATUMUMAB |
| 330009165 | 330005963 | 1.77 | 11.8 | Neo-adjuvant (N) | 2015-10-30 | 2015-10-30 | MABCUTE TRIAL | N | N | 330024946 | DOXORUBICIN + OLARATUMAB |
| 330009166 | 330005963 | 0 | 62.7 | Palliative (P) | 2016-09-08 | 2016-09-15 | Capecitabine + Cisplatin | 02 | N | 330024946 | LENALIDOMIDE |
| 330009167 | 330005963 | 1.57 | null | Palliative (P) | 2013-05-11 | 2013-05-12 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | 330024946 | CARBOPLATIN + VINCRISTINE |
| 330009168 | 330005965 | 1.83 | 85.6 | Curative (C) | 2017-05-31 | 2017-05-31 | UKALL14- Ph 2 Induction | 02 | N | 330024986 | DOXORUBICIN + METHOTREXATE |
| 330009170 | 330005968 | null | 120.4 | Palliative (P) | 2017-12-06 | 2017-12-07 | Dox + HD Mtx (post PAM) | N | N | 330025006 | CISPLATIN + FLUOROURACIL + RT |
| 330009171 | 330005968 | 1.86 | 35.6 | Curative (C) | null | 2015-02-02 | PONATINIB | N | N | 330025006 | CVD |
| 330009172 | 330005968 | 1.92 | 15.7 | Palliative (P) | 2014-04-29 | 2014-05-08 | Cyclophosphamide TBI Allograft | N | N | 330025006 | BORTEZOMIB + RITUXIMAB |
| 330009173 | 330005969 | 1.79 | 0 | null | 2016-09-07 | 2016-09-08 | Bevacizumab + Irinotecan | N | N | 330025015 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE |
| 330009174 | 330005970 | 1.6 | 62.4 | Neo-adjuvant (N) | 2017-12-28 | 2017-12-31 | PCV | 02 | N | 330025020 | PAC-PLAT |
| 330009175 | 330009253 | 1.73 | 77.9 | Curative (C) | 2013-02-05 | 2013-03-17 | VIDE | N | N | 330025020 | RMS 2005 TRIAL |
| 330009176 | 330005974 | null | 58.7 | Adjuvant (A) | 2015-05-28 | 2015-06-26 | Trastuzumab 21 day maintenance | N | N | 330025032 | EMA/CO |
| 330009177 | 330012014 | 1.77 | 75.9 | Curative (C) | 2015-04-16 | 2015-04-19 | LENALIDOMIDE | 2 | N | 330025032 | UKALL 2011 |
| 330009178 | 330005976 | 1.68 | null | null | 2014-08-05 | 2014-08-24 | EMA/CO | N | N | 330025041 | MITOTANE |
| 330009179 | 330009256 | 1.71 | 64.5 | Curative (C) | 2015-06-11 | 2015-06-25 | EMA | 02 | N | 330025041 | EMA/CO |
| 330009180 | 330005979 | 1.82 | 89.6 | Disease modification (D) | 2018-09-16 | 2018-09-29 | CVP R | 02 | N | 330025052 | BEP |
| 330009181 | 330009260 | 1.77 | 84.8 | null | 2018-05-05 | 2018-05-07 | IMMUNOGLOBULIN | Y | N | 330000079 | CHLORAMBUCIL + RITUXIMAB |
| 330009182 | 330009260 | 1.64 | 55.5 | Palliative (P) | 2017-01-11 | 2017-01-18 | MITOTANE | 02 | null | 330000079 | CVD |
| 330009183 | 330009260 | 1.55 | 43.5 | Palliative (P) | 2016-03-05 | 2016-04-12 | IMATINIB | N | N | 330000079 | CAPECITABINE + OXALIPLATIN |